

Bio-Techne to acquire Asuragen

June 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for initial consideration of \$215 million in cash plus contingent consideration of up to \$105 million upon the achievement of certain future milestones.

Asuragen's portfolio of molecular diagnostic and research products include its FDA-cleared AmpliDeX Fragile X Diagnostic and Carrier Screening kit for the screening of prospective parents as potential carriers of Fragile X chromosomal abnormalities and its Quantidex qPCR IS BCR-ABL kit to enable the monitoring of leukemia patients for minimal residual disease.

Asuragen CEO, Matt McManus, will join the Bio-Techne team to continue to lead the legacy Asuragen business as well as the integration process. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.

[Bio-Techne](#), 612-379-2956

[Asuragen](#), 512-681-5200